HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Parker, R. R. Search for Related Content PubMed Articles by Parker, R. R.

Rocky Mountain Spotted Fever: Results of Fifteen Years' Prophylactic Vaccination

The Public Health Service vaccine for the prevention of Rocky Mountain spotted fever is made from virus-laden tissues of infected adults of the Rocky Mountain wood tick, Dermacentor andersoni. The evidence of the protective value of this vaccine is embodied in 3 groups of data covering its use in the Rocky Mountain region and adjacent areas, i.e., throughout the range of its western vector, D. andersoni. The first and by far the most significant set of data concern 15 years' use in the much publicized western Montana area of highly fatal infections; the second, the results of a 2-year test made in 1926 and 1927 in a highly exposed occupational group in a southern Idaho area where the casefatality rate was low; while the third consists of somewhat less significant evidence from 13 years' use in sections of the West other than the western Montana area.¹

¹ So far as the eastern and central states are concerned (D. variabilis areas) the amount of vaccine distributed has been relatively small, no infections have been reported in vaccinated persons, and the conditions attending use have been such that no data are available that bear directly on protective value.